News
News releases
- Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
- Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
- Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI with No FDA-483 Issued
- NDA for Luye Pharma’s Paliperidone Palmitate Extended-release Injectable Suspension Submitted in the U.S.
- Luye Pharma’s Innovative Formulation LY03010 Meets Endpoints in Pivotal U.S. Study
- Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 Soon to Begin Clinical Trials in the U.S.
- Luye Pharma’s Next-Generation VMAT2 Inhibitor LY03015 Soon to Begin Clinical Trials in the U.S.